{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:18:32Z","timestamp":1787912312000,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372639"],"award-info":[{"award-number":["82372639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902328"],"award-info":[{"award-number":["81902328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05638-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:57:06Z","timestamp":1784537826000},"page":"3945-3959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FAL1 facilitates cisplatin resistance of lung adenocarcinoma via BMI1\/BIM-mediated apoptosis\u2013autophagy interaction"],"prefix":"10.1007","volume":"481","author":[{"given":"Teng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1869-5360","authenticated-orcid":false,"given":"Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"1","key":"5638_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"5638_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.molmed.2019.04.012","volume":"25","author":"V Relli","year":"2019","unstructured":"Relli V, Trerotola M, Guerra E, Alberti S (2019) Abandoning the notion of non-small cell lung cancer. Trends Mol Med 25(7):585\u2013594","journal-title":"Trends Mol Med"},{"issue":"3","key":"5638_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.thorsurg.2013.04.005","volume":"23","author":"C Mascaux","year":"2013","unstructured":"Mascaux C, Shepherd FA (2013) Adjuvant chemotherapy after pulmonary resection for lung cancer. Thorac Surg Clin 23(3):401\u2013410","journal-title":"Thorac Surg Clin"},{"issue":"16","key":"5638_CR4","doi-asserted-by":"publisher","first-page":"8885","DOI":"10.3390\/ijms22168885","volume":"22","author":"J Kryczka","year":"2021","unstructured":"Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzezianska-Lasota E (2021) Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci 22(16):8885","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5638_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","volume":"172","author":"F Kopp","year":"2018","unstructured":"Kopp F, Mendell JT (2018) Functional classification and experimental dissection of long noncoding RNAs. Cell 172(3):393\u2013407","journal-title":"Cell"},{"key":"5638_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175317","volume":"934","author":"C Pan","year":"2022","unstructured":"Pan C, Chen G, Zhao X, Xu X, Liu J (2022) LncRNA BBOX1-AS1 silencing inhibits esophageal squamous cell cancer progression by promoting ferroptosis via miR-513a-3p\/SLC7A11 axis. Eur J Pharmacol 934:175317","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"5638_CR7","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.1080\/21655979.2022.2050968","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Pan C, Lu R, Zhang S (2022) Long noncoding RNA ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 antisense RNA 1 recruits enhancer of zeste 2 polycomb repressive complex 2 subunit to promote the proliferation, migration and invasion of lung adenocarcinoma cells. Bioengineered (Austin) 13(3):7868\u20137880","journal-title":"Bioengineered (Austin)"},{"key":"5638_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12935-018-0537-8","volume":"18","author":"B Liu","year":"2018","unstructured":"Liu B, Pan CF, Yao GL, Wei K, Xia Y, Chen YJ (2018) The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma. Cancer Cell Int 18:38","journal-title":"Cancer Cell Int"},{"issue":"1","key":"5638_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000480414","volume":"43","author":"C Pan","year":"2017","unstructured":"Pan C, Yao G, Liu B, Ma T, Xia Y, Wei K, Wang J, Xu J, Chen L, Chen Y (2017) Long noncoding RNA FAL1 promotes cell proliferation, invasion and epithelial-mesenchymal transition through the PTEN\/AKT signaling axis in non-small cell lung cancer. Cell Physiol Biochem 43(1):339\u2013352","journal-title":"Cell Physiol Biochem"},{"key":"5638_CR10","doi-asserted-by":"publisher","first-page":"4693471","DOI":"10.1155\/2016\/4693471","volume":"2016","author":"B Liu","year":"2016","unstructured":"Liu B, Pan CF, He ZC, Wang J, Wang PL, Ma T, Xia Y, Chen YJ (2016) Long noncoding RNA-LET suppresses tumor growth and EMT in lung adenocarcinoma. Biomed Res Int 2016:4693471","journal-title":"Biomed Res Int"},{"key":"5638_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omtn.2021.04.022","volume":"25","author":"J Luo","year":"2021","unstructured":"Luo J, Wang H, Wang L, Wang G, Yao Y, Xie K, Li X, Xu L, Shen Y, Ren B (2021) LncRNA GAS6-AS1 inhibits progression and glucose metabolism reprogramming in LUAD via repressing E2F1-mediated transcription of GLUT1. Mol Ther Nucleic Acids 25:11\u201324","journal-title":"Mol Ther Nucleic Acids"},{"key":"5638_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.omtn.2021.04.003","volume":"24","author":"F Xu","year":"2021","unstructured":"Xu F, Huang X, Li Y, Chen Y, Lin L (2021) m(6)A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids 24:780\u2013791","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"5638_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/15592294.2019.1625673","volume":"14","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Yuan Y, Li Y, Zhang P, Chen P, Sun S (2019) An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma. Epigenetics 14(10):949\u2013960","journal-title":"Epigenetics"},{"key":"5638_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lfs.2018.02.006","volume":"197","author":"B Li","year":"2018","unstructured":"Li B, Mao R, Liu C, Zhang W, Tang Y, Guo Z (2018) LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells. Life Sci 197:122\u2013129","journal-title":"Life Sci"},{"issue":"4","key":"5638_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002592","volume":"95","author":"S Jeong","year":"2016","unstructured":"Jeong S, Lee J, Kim D, Seol MY, Lee WK, Jeong JJ, Nam KH, Jung SG, Shin DY, Lee EJ, Chung WY, Jo YS (2016) Relationship of focally amplified long noncoding on chromosome 1 (FAL1) lncRNA with E2F transcription factors in thyroid cancer. Medicine (Baltimore) 95(4):e2592","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"5638_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ccr.2014.07.009","volume":"26","author":"X Hu","year":"2014","unstructured":"Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L (2014) A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26(3):344\u2013357","journal-title":"Cancer Cell"},{"issue":"19","key":"5638_CR17","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108863","volume":"40","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cadwell K, Cecconi F, Choi AMK, Choi ME, Chu CT, Codogno P, Colombo MI, Cuervo AM, Deretic V, Dikic I, Elazar Z, Eskelinen EL, Fimia GM, Gewirtz DA, Green DR, Hansen M, Jaattela M, Johansen T, Juhasz G, Karantza V, Kraft C, Kroemer G, Ktistakis NT, Kumar S, Lopez-Otin C, Macleod KF, Madeo F, Martinez J, Melendez A, Mizushima N, Munz C, Penninger JM, Perera RM, Piacentini M, Reggiori F, Rubinsztein DC, Ryan KM, Sadoshima J, Santambrogio L, Scorrano L, Simon HU, Simon AK, Simonsen A, Stolz A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Yue Z, Zhong Q, Galluzzi L, Pietrocola F (2021) Autophagy in major human diseases. EMBO J 40(19):EMBJ2021108863","journal-title":"EMBO J"},{"issue":"16","key":"5638_CR18","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMra2022774","volume":"383","author":"N Mizushima","year":"2020","unstructured":"Mizushima N, Levine B (2020) Autophagy in human diseases. N Engl J Med 383(16):1564\u20131576","journal-title":"N Engl J Med"},{"issue":"16","key":"5638_CR19","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.31335","volume":"124","author":"AV Onorati","year":"2018","unstructured":"Onorati AV, Dyczynski M, Ojha R, Amaravadi RK (2018) Targeting autophagy in cancer. Cancer 124(16):3307\u20133318","journal-title":"Cancer"},{"issue":"2","key":"5638_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/CBM-201705","volume":"30","author":"Y Zhong","year":"2021","unstructured":"Zhong Y, Lin H, Li Q, Liu C, Shen J (2021) CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p\/ADAM28 axis. Cancer Biomark 30(2):261\u2013273","journal-title":"Cancer Biomark"},{"issue":"9","key":"5638_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.31083\/ph.2018.8514","volume":"73","author":"F Long","year":"2018","unstructured":"Long F, Liu W, Jia P, Wang H, Jiang G, Wang T (2018) HIF-1alpha-induced autophagy contributes to cisplatin resistance in ovarian cancer cells. Pharmazie 73(9):533\u2013536","journal-title":"Pharmazie"},{"issue":"18","key":"5638_CR22","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1158\/0008-5472.CAN-15-0037","volume":"75","author":"A Shteingauz","year":"2015","unstructured":"Shteingauz A, Boyango I, Naroditsky I, Hammond E, Gruber M, Doweck I, Ilan N, Vlodavsky I (2015) Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res 75(18):3946\u20133957","journal-title":"Cancer Res"},{"issue":"8","key":"5638_CR23","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4161\/auto.5.8.9996","volume":"5","author":"J Song","year":"2009","unstructured":"Song J, Qu Z, Guo X, Zhao Q, Zhao X, Gao L, Sun K, Shen F, Wu M, Wei L (2009) Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 5(8):1131\u20131144","journal-title":"Autophagy"},{"issue":"1","key":"5638_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos WP, Thomas AD, Kaina B (2016) DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer 16(1):20\u201333","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"5638_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s10637-020-01032-y","volume":"39","author":"BM Gasiorkiewicz","year":"2021","unstructured":"Gasiorkiewicz BM, Koczurkiewicz-Adamczyk P, Piska K, Pekala E (2021) Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer. Invest New Drugs 39(2):538\u2013563","journal-title":"Invest New Drugs"},{"key":"5638_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejps.2019.04.011","volume":"134","author":"NM Kocaturk","year":"2019","unstructured":"Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O (2019) Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci 134:116\u2013137","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"5638_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1124\/pr.111.005637","volume":"64","author":"DW Shen","year":"2012","unstructured":"Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64(3):706\u2013721","journal-title":"Pharmacol Rev"},{"issue":"6","key":"5638_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/bjc.1997.154","volume":"75","author":"PB Jensen","year":"1997","unstructured":"Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 75(6):869\u2013877","journal-title":"Br J Cancer"},{"issue":"2","key":"5638_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2478\/raon-2019-0018","volume":"53","author":"T Makovec","year":"2019","unstructured":"Makovec T (2019) Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 53(2):148\u2013158","journal-title":"Radiol Oncol"},{"issue":"10","key":"5638_CR30","doi-asserted-by":"publisher","first-page":"8481","DOI":"10.1002\/jcb.27074","volume":"119","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhao Z, Zhang S, Li Z, Li D, Yang S, Zhang H, Zeng X, Liu J (2018) LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma. J Cell Biochem 119(10):8481\u20138489","journal-title":"J Cell Biochem"},{"issue":"11","key":"5638_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/iub.1880","volume":"70","author":"K Wu","year":"2018","unstructured":"Wu K, Zhang N, Ma J, Huang J, Chen J, Wang L, Zhang J (2018) Long noncoding RNA FAL1 promotes proliferation and inhibits apoptosis of human colon cancer cells. IUBMB Life 70(11):1093\u20131100","journal-title":"IUBMB Life"},{"issue":"1","key":"5638_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-020-01000-2","volume":"13","author":"H Chang","year":"2020","unstructured":"Chang H, Zou Z (2020) Targeting autophagy to overcome drug resistance: further developments. J Hematol Oncol 13(1):159","journal-title":"J Hematol Oncol"},{"issue":"19","key":"5638_CR33","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.7150\/thno.27806","volume":"8","author":"F Zhou","year":"2018","unstructured":"Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, Lv X, Li J, Chen B (2018) Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics 8(19):5200\u20135212","journal-title":"Theranostics"},{"key":"5638_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijbiomac.2022.02.005","volume":"204","author":"K Prerna","year":"2022","unstructured":"Prerna K, Dubey VK (2022) Beclin1-mediated interplay between autophagy and apoptosis: new understanding. Int J Biol Macromol 204:258\u2013273","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"5638_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12943-019-1017-z","volume":"18","author":"S Xu","year":"2019","unstructured":"Xu S, Wang P, Zhang J, Wu H, Sui S, Zhang J, Wang Q, Qiao K, Yang W, Xu H, Pang D (2019) Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cancer 18(1):89","journal-title":"Mol Cancer"},{"key":"5638_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ijbiomac.2018.09.051","volume":"122","author":"L Xin","year":"2019","unstructured":"Xin L, Zhou LQ, Liu L, Yuan YW, Zhang HT, Zeng F (2019) METase promotes cell autophagy via promoting SNHG5 and suppressing miR-20a in gastric cancer. Int J Biol Macromol 122:1046\u20131052","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"5638_CR37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.bbrc.2018.02.141","volume":"497","author":"Y Yang","year":"2018","unstructured":"Yang Y, Jiang C, Yang Y, Guo L, Huang J, Liu X, Wu C, Zou J (2018) Silencing of LncRNA-HOTAIR decreases drug resistance of non-small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun 497(4):1003\u20131010","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"5638_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/15384101.2021.2020433","volume":"21","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang X, Du S (2022) Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2. Cell Cycle 21(4):368\u2013378","journal-title":"Cell Cycle"},{"key":"5638_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144886","volume":"755","author":"J Fu","year":"2020","unstructured":"Fu J, Cai H, Wu Y, Fang S, Wang D (2020) Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p\/WEE1 axis. Gene 755:144886","journal-title":"Gene"},{"issue":"5","key":"5638_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00280-019-03808-3","volume":"83","author":"L Chen","year":"2019","unstructured":"Chen L, Han X, Hu Z, Chen L (2019) The PVT1\/miR-216b\/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis. Cancer Chemother Pharmacol 83(5):921\u2013931","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"5638_CR41","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.3390\/ijms23169367","volume":"23","author":"H Wang","year":"2022","unstructured":"Wang H, Zhang Y (2022) The crucial roles of Bmi-1 in cancer: implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int J Mol Sci 23(16):9367","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"5638_CR42","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1038\/onc.2009.42","volume":"27","author":"JD Pinon","year":"2008","unstructured":"Pinon JD, Labi V, Egle A, Villunger A (2008) Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 27(Suppl 1):S41-52","journal-title":"Oncogene"},{"issue":"12","key":"5638_CR43","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1158\/1535-7163.MCT-09-0685","volume":"8","author":"T Akiyama","year":"2009","unstructured":"Akiyama T, Dass CR, Choong PF (2009) Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 8(12):3173\u20133180","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"5638_CR44","doi-asserted-by":"publisher","first-page":"815","DOI":"10.7150\/ijbs.20052","volume":"13","author":"M Farhan","year":"2017","unstructured":"Farhan M, Wang H, Gaur U, Little PJ, Xu J, Zheng W (2017) FOXO signaling pathways as therapeutic targets in cancer. Int J Biol Sci 13(7):815\u2013827","journal-title":"Int J Biol Sci"},{"issue":"25","key":"5638_CR45","doi-asserted-by":"publisher","first-page":"22384","DOI":"10.1074\/jbc.M111.239566","volume":"286","author":"J Wang","year":"2011","unstructured":"Wang J, Zhou JY, Wu GS (2011) Bim protein degradation contributes to cisplatin resistance. J Biol Chem 286(25):22384\u201322392","journal-title":"J Biol Chem"},{"issue":"2","key":"5638_CR46","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/15548627.2014.998892","volume":"11","author":"Y Dai","year":"2015","unstructured":"Dai Y, Grant S (2015) BCL2L11\/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy 11(2):416\u2013418","journal-title":"Autophagy"},{"issue":"21","key":"5638_CR47","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1111\/j.1742-4658.2009.07329.x","volume":"276","author":"AS Gillings","year":"2009","unstructured":"Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ (2009) Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 276(21):6050\u20136062","journal-title":"FEBS J"},{"key":"5638_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.799392","volume":"10","author":"D Gatica","year":"2022","unstructured":"Gatica D, Lahiri V, Klionsky DJ (2022) The role of non-coding RNAs in autophagy during carcinogenesis. Front Cell Dev Biol 10:799392","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"5638_CR49","first-page":"114","volume":"48","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Chen L (2022) The role of interaction between autophagy and apoptosis in tumorigenesis (Review). Oncol Rep 48(4):114","journal-title":"Oncol Rep"},{"issue":"9","key":"5638_CR50","first-page":"5252","volume":"12","author":"B Sheng","year":"2020","unstructured":"Sheng B, Song Y, Zhang J, Li R, Wang Z, Zhu X (2020) Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. Am J Transl Res 12(9):5252\u20135268","journal-title":"Am J Transl Res"},{"key":"5638_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep05382","volume":"4","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Sun K, Ma Y, Yang H, Zhang Y, Kong X, Wei L (2014) Autophagy inhibits chemotherapy-induced apoptosis through downregulating Bad and Bim in hepatocellular carcinoma cells. Sci Rep 4:5382","journal-title":"Sci Rep"},{"issue":"17","key":"5638_CR52","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2014-03-564534","volume":"124","author":"S Chen","year":"2014","unstructured":"Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S (2014) A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124(17):2687\u20132697","journal-title":"Blood"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05638-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:02:49Z","timestamp":1787911369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05638-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["5638"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05638-3","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical samples used to study were collected from the First Affiliated Hospital of Nanjing Medical University, and were supervised by the Ethic Committee of Nanjing Medical University. All animal experiments were approved by the Animal Care and Use Committee of the First Affiliated Hospital of Nanjing Medical University.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}